The Nobel Prize in Chemistry has been awarded to David Baker, Demis Hassabis, and John Jumper for their contributions to computational protein design and structure prediction. Their work in protein folding has the potential to revolutionize drug development and therapeutic treatments.
Alnylam Pharmaceuticals has submitted an application to the FDA for the approval of vutrisiran, a drug used to treat nerve damage associated with transthyretin amyloidosis.
Johnson & Johnson has terminated its Sunrise-2 trial for TAR-200, a drug delivery system for bladder cancer treatment, as it did not outperform traditional chemotherapy and radiation.
Gemma Biotherapeutics has partnered with Brazil's Fiocruz to enhance the distribution of gene therapies for rare diseases in Brazil.
AstraZeneca has acquired the rights to a preclinical oral cholesterol-lowering drug targeting lipoprotein(a) from CPSC Pharmaceutical Group.
Astellas has secured rights to an experimental gene therapy for frontotemporal dementia from AviadoBio.
These developments reflect the pharmaceutical industry's focus on innovative solutions to address complex health challenges.